Anti-Hypertensive Drugs - Estonia

Estonia

The Anti-Hypertensive Drugs market in Estonia is projected to achieve a revenue of US$5.30m in 2024.
It is expected to witness an annual growth rate (CAGR 2024-2029) of 0.08%, leading to a market volume of US$5.32m by 2029.
In terms of global comparison, United States will generate the highest revenue, amounting to US$12,290.00m in 2024.
Estonia's increasing focus on preventive healthcare has led to a rising demand for anti-hypertensive drugs in the country.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Estonia has been on the rise in recent years.

Customer preferences: Estonian consumers are increasingly opting for anti-hypertensive drugs due to the rising prevalence of hypertension in the country. Additionally, the aging population is also contributing to the growing demand for these drugs.

Trends in the market: The market for anti-hypertensive drugs in Estonia is witnessing a shift towards combination therapies. This is because combination therapies are more effective in controlling hypertension than monotherapies. Moreover, the market is also witnessing a trend towards the use of generic drugs due to their affordability.

Local special circumstances: Estonia has a well-established healthcare system that provides universal healthcare coverage to its citizens. The government has implemented several initiatives to promote the use of generic drugs in the country. This has led to the increased availability and affordability of anti-hypertensive drugs in Estonia.

Underlying macroeconomic factors: Estonia has a stable economy with a high standard of living. The country has a high literacy rate and a well-educated workforce. Additionally, the government has implemented several policies to promote the growth of the pharmaceutical industry in the country. These factors have contributed to the growth of the anti-hypertensive drugs market in Estonia.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.